WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Online Marketing Friday, March 29, 2024 
Add Press Release News | News Feeds Feeds | Email This News Email


Global Renal Cell Cancer (RCC) Disease Forecast and Market 2019-2038: Sutent Continues to be the Most Widely Prescribed Therapy in Locally Advanced and Metastatic RCC
Wednesday, June 19, 2019

DUBLIN, June 19, 2019 /PRNewswire/ -- The "Renal cell cancer (RCC) disease forecast and market analysis to 2038" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Renal cell carcinoma (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms tumor (nephroblastoma).

The incidence of RCC is higher in those over the age of 60 years, suggesting that the aging population may play a significant role in current and future disease burden. Overall, RCC incidence rates have been steadily increasing in both men and women in the US, Japan, and five major EU markets since the 1970s.

Market Snapshot

    --  The PD-1/PD-L1 class is set to experience significant growth, with
        annual sales forecast to reach $3.2bn by 2026.
    --  Sutent continues to be the most widely prescribed therapy in locally
        advanced and metastatic RCC.
    --  Incident cases of RCC are expected to increase by around a quarter
        during 2018-38.
    --  Numerous therapies will soon experience generic erosion with the
        expiries of key patents.
    --  PD-1/PD-L1 therapies are set to dominate the first-line treatment of
        advanced RC
    --  Combination therapies pose challenges for payers.

Key Topics Covered:

Overview
Recent Forecast Updates
Market Dynamics
Forecast And Future Trends
Market Definition And Methodology
Primary Research Methodology
Bibliography
Product Profile: Afinitor
Product Profile: Avastin
Product Profile (Late Stage): Bavencio
Product Profile (Late Stage): Cb-839
Product Profile: Cabometyx
Product Profile: Fotivda
Product Profile: Inlyta
Product Profile (Late Stage): Keytruda
Product Profile: Lenvima
Product Profile: Nexavar
Product Profile: Opdivo
Product Profile: Sutent
Product Profile (Late Stage): Tecentriq
Product Profile: Torisel
Product Profile: Votrient
Product Profile (Late Stage): Abexinostat

Treatment: Renal Cell Carcinoma (Published On 16 February 2018)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Current Treatment Options
Prescribing Trends

Epidemiology: Renal Cell Carcinoma (Published On 06 March 2019)
Overview
Disease Background
Methodology
Forecast
Bibliography
Appendix: Additional Sources

Marketed Drugs: Renal Cell Carcinoma (Published On 06 March 2019)
Overview
Product Overview
Product Profile: Afinitor
Product Profile: Avastin
Product Profile: Cabometyx
Product Profile: Fotivda
Product Profile: Inlyta
Product Profile: Lenvima
Product Profile: Nexavar
Product Profile: Opdivo
Product Profile: Sutent
Product Profile: Torisel
Product Profile: Votrient

Renal Cell Cancer Pricing, Reimbursement, And Access (Published On 22 August 2018)
Overview
Regulatory Labels
Global Access Levers
Evidence And Value
Access To Recently Approved And Pipeline Drugs
Pricing
US
Canada
Japan
France
Germany
Italy
Spain
UK
Methodology

Pipeline: Renal Cell Carcinoma (Published On 06 March 2019)
Overview
Clinical Pipeline Overview
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Bavencio
Product Profile (Late Stage): Cb-839
Product Profile (Late Stage): Keytruda
Product Profile (Late Stage): Tecentriq
Product Profile (Late Stage): Abexinostat

For more information about this report visit https://www.researchandmarkets.com/r/2og07l

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-renal-cell-cancer-rcc-disease-forecast-and-market-2019-2038-sutent-continues-to-be-the-most-widely-prescribed-therapy-in-locally-advanced-and-metastatic-rcc-300871166.html

SOURCE Research and Markets



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav JND eDiscovery Receives National Law Journal Hall of Fame Award in Two Categories | Mar 29, 2024
Nav Trip.com's Global 3.3 Promotion Sees Record Success in Asia and Europe | Mar 29, 2024
Nav Europe Fibercos and Towercos Market Dynamics Report 2024: Lessons Learned and Key Takeaways for Telcos and Infrastructure Companies | Mar 29, 2024
Nav China Non-Invasive Prenatal Testing Analysis Report 2024: Testing Volume 2018-2032 and Market Estimation Forecasts 2024-2032 with Focus on Mergers & Acquisitions, Collaborations, and Partnerships | Mar 29, 2024
Nav Global Highly Potent API (Active Pharmaceutical Ingredient) Industry Research 2023-2033: Advancements in Containment Technologies, and Increasing Investment for Manufacturing Units | Mar 29, 2024
Nav Exclusive Networks announces a major step in its growth strategy in APAC with NEXTGEN Group acquisition | Mar 29, 2024
Nav United States Self-Monitoring Blood Glucose Devices Market Research 2023-2032: SMBG Devices and CGM Systems Surge - The Shift from Traditional Blood Glucose Meters | Mar 29, 2024
Nav "Bleach: Brave Souls" Thousand-Year Blood War Zenith Summons: Reinforcements Featuring Meninas, Rangiku, and Yumichika Begins March 31 Alongside a Spring Festival Campaign | Mar 29, 2024
Nav Evolution enters Delaware through Rush Street Interactive | Mar 29, 2024
Nav IDTechEx Discusses the Sustainability of Electric Vehicle Fire Protection Materials | Mar 29, 2024
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News